Cardiovascular Outcomes in Participants With Type 2 Diabetes Mellitus (T2DM)

NCT03249506 · clinicaltrials.gov ↗

COMPLETED

Status

25358

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG: Canagliflozin
DRUG: Empagliflozin
DRUG: Dapagliflozin
DRUG: Dipeptidyl Peptidase-4 Inhibitor (DPP-4)
DRUG: Glucagon-Like Peptide-1 Agonist (GLP-1)
DRUG: Thiazolidinedione (TZD)
DRUG: Sulfonylureas
DRUG: Insulin

Sponsor

Janssen Research & Development, LLC